Management of severe osteoporosis

Expert Opin Pharmacother. 2016;17(4):473-88. doi: 10.1517/14656566.2016.1124856. Epub 2015 Dec 23.

Abstract

Introduction: Severe osteoporosis represents a disease of high mortality and morbidity. Recognition of what constitutes and causes severe osteoporosis and aggressive intervention with pharmacological agents with evidence to reduce fracture risk are outlined in this review.

Areas covered: This review is a blend of evidence obtained from literature searches from PubMed and The National Library of Medicine (USA), clinical experience and the author's opinions. The review covers the recognition of what constitutes severe osteoporosis, and provides up-to-date references on this sub-set of high risk patients.

Expert opinion: Severe osteoporosis can be classified by using measurements of bone densitometry, identification of prevalent fractures, and, knowledge of what additional risk factors contribute to high fracture risk. Once recognized, the potential consequences of severe osteoporosis can be mitigated by appropriate selection of pharmacological therapies and modalities to reduce the risk for falling.

Keywords: Management of severe osteoporosis; pharmacological therapy of severe osteoporosis; severe osteoporosis; treatment of high risk osteoporotic patients.

Publication types

  • Review

MeSH terms

  • Accidental Falls / prevention & control
  • Bone Density / drug effects
  • Disease Management
  • Female
  • Fractures, Bone / etiology
  • Fractures, Bone / prevention & control
  • Humans
  • Male
  • Osteoporosis / complications
  • Osteoporosis / drug therapy*
  • Osteoporosis / physiopathology
  • Osteoporosis, Postmenopausal / complications
  • Osteoporosis, Postmenopausal / drug therapy
  • Osteoporosis, Postmenopausal / physiopathology
  • Risk Factors
  • Severity of Illness Index